RNF168

Across TCGA pan-cancer cohorts, RNF168 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RNF168 data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher RNF168 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RNF168 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

COAD, LUSC, and LIHC are the cancer types where RNF168 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.155	0.874	<.001	13	view →
LUSC	DFS	Median	All	0.266	0.662	.010	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
BLCA	OS	Median	IV	0.130	0.599	.002	6	view →
UCEC	DFS	Median	All	0.951	0.613	.022	4	view →
READ	DFS	Median	All	0.196	0.568	.045	3	view →
LUAD	DFS	Median	All	0.213	0.676	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RNF168–COAD (OS)

Open the COAD breakdown →